검색어: cyclooxygenase (영어 - 에스토니아어)

cyclooxygenase is responsible for generation of prostaglandins.
ensüüm tsüklooksügenaas vastutab prostaglandiinide moodustumise eest.

the cyclooxygenase enzyme (cox) is present in two forms.
tsüklooksügenaasensüüm (cox) esineb kahes vormis.

the principal mode of action is inhibition of cyclooxygenase (cox).
peamine toimimisviis on tsüklooksügenaasi (cox) inhibeerimine.

zubrin acts by blocking enzymes, cyclooxygenase-1 and cyclooxygenase-2.
zubrin toimib ensüümide tsüklooksügenaas-1 ja tsüklooksügenaas-2 blokeerimise kaudu.

cyclooxygenase 1 (cox-1) is only inhibited to a small extent.
tsüklooksügenaasi 1 (cox-1) inhibeeritakse vaid vähesel määral.

celecoxib is an oral, selective cyclooxygenase-2 (cox-2) inhibitor.
tselekoksiib on suukaudselt manustatav tsüklooksügenaas-2 (cox-2) selektiivne inhibiitor.

meloxicam acts by blocking an enzyme called cyclooxygenase which is involved in the production of prostaglandins.
meloksikaam blokeerib prostaglandiinide tekkes osaleva ensüümi tsüklooksügenaasi.

tepoxalin is a dual cyclooxygenase / 5-lipoxygenase inhibitor with anti-inflammatory activity.
tepoksaliin on põletikuvastase toimega tsüklooksügenaasi / 5- lipooksügenaasi inhibiitor.

it is a potent and selective inhibitor of the cyclooxygenase 2 enzyme (cox-2).
see on tsüklooksügenaas 2 ensüümi (cox-2) jõuline ja selektiivne inhibiitor.

reproduction is authorised provided the source is acknowledged. cyclooxygenase-2 (cox-2).
reproduction is authorised provided the source is acknowledged.

amfenac inhibits the action of prostaglandin h synthase (cyclooxygenase), an enzyme required for prostaglandin production.
amfenak pärsib prostaglandiini moodustumiseks vajaliku ensüümi prostaglandiin h süntaasi (tsüklooksügenaasi) toimet.

valdecoxib is a selective cyclooxygenase-2 (cox-2) inhibitor within the clinical dose range.
valdekoksiib on selektiivne tsüklooksügenaas-2 (cox-2) inhibiitor.

it selectively inhibits the cyclooxygenase 2 enzyme (cox-2), which is responsible for pain, inflammation or fever.
see inhibeerib selektiivselt tsüklooksügenaas 2 ensüümi (cox-2), mis on vastutav valu, põletiku ja palaviku tekkes.

also, it has been demonstrated in vitro that high-dose nsaids (cyclooxygenase inhibitors) can block the macrophage activating effect of liposomal mifamurtide.
lisaks on in vitro näidatud, et nsaid-ide (tsüklooksügenaasi inhibiitorid) suurte annuste manustamine võib blokeerida liposomaalse mifamurtiidi makrofaage aktiveerivat toimet.

the cyclooxygenase 1 enzyme (cox-1) which has protective functions, for example, in the digestive tract and kidneys, is not inhibited by cimicoxib.
tsimikoksiib ei inhibeeri ensüüm tsüklooksügenaas-1 (cox-1), millel on kaitsev toime näiteks seedetraktis ja neerudes.

in vitro and in vivo studies demonstrated that meloxicam inhibits cyclooxygenase-2 (cox-2) to a greater extent than cyclooxygenase-1 (cox-1).
in vitro ja in vivo uuringutes inhibeeris meloksikaam tsüklooksügenaasi 2 (cox-2) rohkem kui tsüklooksügenaasi 1 (cox-1).